Cardiac Sarcoidosis: When and How to Treat Inflammation
Cardiac Failure Review · 22.11.2021 · 7
DOI: 10.15420/cfr.2021.16 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiac Failure Review, online erschienen am 22.11.2021. Verfasst von Gerard T Giblin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Heart Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, MA, US. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Harvard Catalyst.
Abstract (Originalsprache)
Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Advanced Heart Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, MA, US.
- Cardiovascular Imaging Program and Departments of Medicine and Radiology, Brigham and Women's Hospital, Harvard Medical School Boston, MA, US.
- Cardiac Arrhythmia Service, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, MA, US.
- Interstitial Lung Disease Program, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, MA, US.
Förderung
- NIA NIH HHS
- Harvard Catalyst
Zitieren
APA
Giblin, G. T., Murphy, L., Stewart, G. C., Desai, A. S., Di Carli, M. F., Blankstein, R., Givertz, M. M., Tedrow, U. B., Sauer, W. H., Hunninghake, G. M., Dellaripa, P. F., Divakaran, S., & Lakdawala, N. K. (2021). Cardiac Sarcoidosis: When and How to Treat Inflammation. Cardiac Failure Review, 7. https://doi.org/10.15420/cfr.2021.16
Vancouver
Giblin GT, Murphy L, Stewart GC, Desai AS, Di Carli MF, Blankstein R, et al. Cardiac Sarcoidosis: When and How to Treat Inflammation. Cardiac Failure Review. 2021;7. doi:10.15420/cfr.2021.16
BibTeX
@article{Giblin2021,
author = {Giblin, Gerard T and Murphy, Laura and Stewart, Garrick C and Desai, Akshay S and Di Carli, Marcelo F and Blankstein, Ron and Givertz, Michael M and Tedrow, Usha B and Sauer, William H and Hunninghake, Gary M and Dellaripa, Paul F and Divakaran, Sanjay and Lakdawala, Neal K},
title = {Cardiac Sarcoidosis: When and How to Treat Inflammation},
journal = {Cardiac Failure Review},
year = {2021},
volume = {7},
doi = {10.15420/cfr.2021.16}
}
EUVIMED